Yahoo · Oct 27, 2026
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.
IO
NASDAQ · IOVA
Iovance Biotherapeutics, Inc.
Healthcare · Biotechnology
$9.56
Down-$5.25 (-35.45%)
Updated Oct 30, 2026, 9:32 AM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 744.64M
- P/E ratio
- -1.93
- Dividend yield
- 0.00%
- 52-week range
- $1.76 – $15.37
- Volume
- 59.23M
- Avg. volume
- 13.69M
Price performance · IOVA
IOVA price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
IOVA closed at $9.56 after 21 trading sessions, down 32.82% for the selected period.
- Last close
- $9.56
- Period change
- -32.82%
- Period low
- $9.56
- Period high
- $14.86
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $10.70 | $11.58 | $9.345 | $9.56 | 59.23M |
| Oct 28, 2026 | $14.30 | $14.91 | $14.18 | $14.81 | 9.71M |
| Oct 27, 2026 | $13.74 | $14.78 | $13.59 | $14.58 | 8.8M |
| Oct 26, 2026 | $14.20 | $14.20 | $13.3234 | $13.78 | 7.44M |
| Oct 23, 2026 | $14.185 | $14.30 | $13.54 | $14.09 | 7.76M |
| Oct 22, 2026 | $14.405 | $14.6984 | $13.64 | $14.14 | 10.77M |
| Oct 21, 2026 | $14.945 | $15.37 | $14.59 | $14.62 | 11.01M |
| Oct 20, 2026 | $14.18 | $14.955 | $13.83 | $14.86 | 9.75M |
| Oct 19, 2026 | $13.80 | $14.74 | $13.78 | $14.21 | 8.51M |
| Oct 16, 2026 | $14.65 | $14.71 | $13.515 | $13.62 | 12.19M |
| Oct 15, 2026 | $14.01 | $14.74 | $13.8047 | $14.72 | 11.52M |
| Oct 14, 2026 | $14.35 | $14.64 | $14.15 | $14.21 | 10.63M |
| Oct 13, 2026 | $14.483 | $14.80 | $14.31 | $14.50 | 11.92M |
| Oct 12, 2026 | $14.50 | $14.82 | $14.20 | $14.56 | 9.11M |
| Oct 9, 2026 | $13.36 | $14.94 | $13.29 | $14.62 | 16.99M |
| Oct 8, 2026 | $12.645 | $13.395 | $12.62 | $13.31 | 14.82M |
| Oct 7, 2026 | $12.515 | $13.148 | $12.31 | $12.915 | 14.53M |
| Oct 6, 2026 | $14.21 | $14.21 | $12.92 | $12.96 | 18.95M |
| Oct 5, 2026 | $14.03 | $14.405 | $13.71 | $14.15 | 11.75M |
| Oct 2, 2026 | $14.45 | $14.75 | $13.95 | $14.215 | 11.92M |
| Oct 1, 2026 | $14.755 | $15.03 | $14.19 | $14.23 | 15.97M |
Latest IOVA news
The latest Smart Investors Daily articles mentioning IOVA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
IOVA research
Overview
Company profile and research snapshot.
Company profile
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $14.25
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | Barclays | Overweight | — |
| Oct 8, 2026 | Baird | Neutral | — |
| Sep 30, 2026 | Wells Fargo | Overweight | — |
| Sep 29, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 24, 2026 | Goldman Sachs | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 27, 2026
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, November 5, 2026 at 8:30 a.m. ET to report its third quarter 2026 financial results and corporate updates. To listen to the live or archived audio webcast, please regis
Yahoo · Oct 26, 2026
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Unprecedented Efficacy in Both Refractory Undifferentiated Pleomorphic Sarcoma (UPS) and Dedifferentiated Liposarcoma (DDLPS) PHILADELPHIA and MADRID, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor
Benzinga · Oct 26, 2026
Iovance Biotherapeutics Reports Deep, Durable Responses With Lifileucel Monotherapy In Metastatic UPS And DDLPS At ESMO 2026
50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026Unprecedented Efficacy in Both Refractory Undifferentiated
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
